白念珠菌对棘白菌素类药物耐药机制的研究进展  

Mechanisms underlying the resistance of Candida albicans to echinocandin antifungals

作　　者：杨璐 段志敏 李岷 Yang Lu;Duan Zhimin;Li Min(Jiangsu Key Laboratory of Molecular Biology for Shkin Diseases and STls,Institute of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing 210042,China)

机构地区：[1]中国医学科学院、北京协和医学院皮肤病研究所、江苏省皮肤病与性病分子生物学重点实验室,南京210042

出　　处：《中华皮肤科杂志》2022年第12期1114-1117,共4页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81773338);中国医学科学院医学与健康科技创新工程项目(2017-I2M-1-017);南京市国家级临床医学中心培育计划项目(2019060001)。

摘　　要：随着棘白菌素类抗真菌药物的应用,对其耐药的白念珠菌菌株越来越多。已发现白念珠菌对棘白菌素类药物耐药主要与FKS突变、MSH2突变、ERG3突变及生物膜形成、细胞自身应激反应、几丁质含量增高、膜鞘脂合成等相关。本文综述白念珠菌相关耐药基因及可能的耐药调控机制,有助于临床克服和预防棘白菌素耐药,探索治疗白念珠菌感染的新靶点,开发新药物。With the application of echinocandin antifungals,more and more resistant Candida albicans strains have been detected.It has been reported that mechanisms underlying the resistance of Candida albicans to echinocandin antifungals mainly involve FKS,MSH2 and ERG3 gene mutations,biofilm formation,cellular stress response,compensatory increases in chitin,sphingolipid synthesis,etc.This review focuses on echinocandin resistance-related genes and underlying mechanisms in Candida albicans,which will help to overcome and prevent echinocandin resistance in clinical practice,and explore new therapeutic targets and drugs for Candida albicans infection.

关 键 词：白色念珠菌 抗药性 真菌 棘白菌素类 点突变 FKS 

分 类 号：R379.4[医药卫生—病原生物学]